Feature | March 06, 2013| Dave Fornell

The Radial Access Adoption Report Card

Over the past decade in the United States, there has been growing interest in transradial artery percutaneous access as a way to significantly reduce bleeding rates and access site complications. However, adoption in the United States has been slow compared to other parts of the world, partly due to lack of training in interventional programs until recently. In articles and sessions at various cardiology conferences, I have heard varying U.S. adoption rate percentages.  

One of the biggest advocates for expanding radial access is Sunil V. Rao, M.D., FACC, assistant professor of medicine at Duke University Medical Center and director of the cardiac cath lab at the Durham VA Medical Center, Durham, N.C. He asked the same question about U.S. radial access usage and found it accounted for 3 percent of cath lab access in his 2008 study[1] of the American College of Cardiology’s CathPCI Registry of the National Cardiovascular Data Registry (NCDR). The CathPCI Registry collects data from about 85 percent of the cardiac cath labs in the United States.

Since 2008, there has been a big push from radial evangelists such as Rao and others to spread the word about the benefits of radial access.  That message has been amplified in recent years in an era of reduced reimbursements and healthcare reform forcing hospitals to look for new ways to reduce costs, including reducing hospital length of stay and complications.

An updated NCDR snapshot of radial access between January 2010 and June 2011 was published in December 2012.  The study showed radial access usage rose to 8.3 percent[2], based on a review of 1.1 million patients undergoing diagnostic cardiac catheterization and 941,248 undergoing percutaneous coronary intervention (PCI). 

This growth rate combined with the introduction of radial training programs in recent years has some experts now predicting a 15 percent radial access usage rate by 2014. 

I wrote a column three years ago that asked why radial access is not more widely used if study after study shows it can slash complication rates, increase patient safety and reduce length of stay and nursing time?  The question I posed then still stands. Out of all the columns and articles ever written in DAIC, that column generated, by far, the most reader comments we ever received. DAIC’s most read website content also includes several transradial access stories in the top 20 articles for 2012. 

One major change that could spur radial’s increased usage would be recognition of its benefits by the Centers for Medicare and Medicaid Services (CMS) by offering higher reimbursements for radial over femoral access. From the level of evidence seen in studies, this increased cost would be offset downstream by greatly lowering the costs to treat complications. 

 

References: 

 

1. Sunil V. Rao, Fang-Shu Ou, Tracy Y. Wang, et al. “Trends in the Prevalence and Outcomes of Radial and Femoral Approaches to Percutaneous Coronary Intervention.” J Am Coll Cardiol Intv. 2008;1(4):379-386. doi:10.1016/j.jcin.2008.05.007.

2. Gregory J. Dehmer, Douglas Weaver, Matthew T. Roe, et al. “A Contemporary View of Diagnostic Cardiac Catheterization and Percutaneous Coronary Intervention in the United States A Report From the CathPCI Registry of the National Cardiovascular Data Registry, 2010 Through June 2011.” J Am Coll Cardiol. 2012;60(20):2017-2031. doi:10.1016/j.jacc.2012.08.966

 

Related Content

Videos | Cath Lab| January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab| January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab| November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab| November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab| October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System
Technology | Cath Lab| October 26, 2017
Corindus Vascular Robotics Inc. announced that it will incorporate the HeartFlow FFRct (fractional flow reserve-...
Shockwave Medical Announces $35 Million in New Financing
News | Cath Lab| October 24, 2017
October 24, 2017 — Shockwave Medical reported $35 million in new financing, an extension of the company’s previously
Overlay Init